Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 266 articles:
HTML format



Single Articles


    September 2021
  1. VICKERS AJ
    Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2021 Sep 29. pii: S0302-2838(21)02050.
    PubMed    


  2. MONTORSI F, Gandaglia G, Briganti A
    Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.026.
    Eur Urol. 2021 Sep 28. pii: S0302-2838(21)02051.
    PubMed    


  3. REN S, Yang B, Wang D
    Re: Vicenc Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33.
    Eur Urol. 2021 Sep 25. pii: S0302-2838(21)02018.
    PubMed    


  4. TRELLES CR, Martinez-Pineiro L
    Re: The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Eur Urol. 2021 Sep 24. pii: S0302-2838(21)02000.
    PubMed    


  5. HAGENS MJ, van Leeuwen PJ
    A Future Prebiopsy Imaging-guided Pathway to Safely Omit Systematic Biopsies and Prevent Diagnosis of Indolent Prostate Cancer.
    Eur Urol. 2021 Sep 21. pii: S0302-2838(21)02002.
    PubMed    


  6. LANTZ A, Bock D, Akre O, Angenete E, et al
    Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.
    Eur Urol. 2021 Sep 15. pii: S0302-2838(21)01928.
    PubMed     Abstract available


  7. GHALI F, Kane CJ
    Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality.
    Eur Urol. 2021 Sep 14. pii: S0302-2838(21)01999.
    PubMed    


  8. ALAN MCNEILL S, Gallagher KM, Clyde D
    Re: A Biochemical Definition of Cure After Brachytherapy for Prostate Cancer.
    Eur Urol. 2021 Sep 13. pii: S0302-2838(21)01995.
    PubMed    


  9. SHOAG JE, Hill A, Jung JH, Spratt D, et al
    Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial.
    Eur Urol. 2021 Sep 10. pii: S0302-2838(21)01988.
    PubMed    


  10. KWAN EM, Spain L, Anton A, Gan CL, et al
    Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01979.
    PubMed     Abstract available


  11. THURTLE D, Jenkins V, Freeman A, Pearson M, et al
    Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01933.
    PubMed     Abstract available


  12. HOPSTAKEN JS, Bomers JGR, Sedelaar MJP, Valerio M, et al
    An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
    Eur Urol. 2021 Sep 3. pii: S0302-2838(21)01949.
    PubMed     Abstract available


    August 2021
  13. EMMETT L, Buteau J, Papa N, Moon D, et al
    The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Eur Urol. 2021 Aug 28. pii: S0302-2838(21)01946.
    PubMed     Abstract available


  14. VAN POPPEL H, Roobol MJ, Chapple CR, Catto JWF, et al
    Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Aug 15. pii: S0302-2838(21)01927.
    PubMed     Abstract available


  15. LORENTE D, Llacer C, Lozano R, de Velasco G, et al
    Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Aug 6. pii: S0302-2838(21)01917.
    PubMed     Abstract available


  16. VENTIMIGLIA E, Pozzi E, Alfano M, Montorsi F, et al
    Re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. Eur Urol 2021;79:826-36.
    Eur Urol. 2021;80:e53-e54.
    PubMed    


  17. GUPTA S, Pitel BA, Knight SM, Halling KC, et al
    Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468-77.
    Eur Urol. 2021;80:e62-e63.
    PubMed    


  18. LUNDY SD, Vij SC, Eng C
    Reply to Eugenio Ventimiglia, Edoardo Pozzi, Massimo Alfano, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Micro
    Eur Urol. 2021;80:e55-e56.
    PubMed    


    July 2021
  19. HADASCHIK B, Herrmann K
    Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Jul 23. pii: S0302-2838(21)01885.
    PubMed    


  20. VICKERS AJ
    Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2021 Jul 19. pii: S0302-2838(21)01867.
    PubMed     Abstract available


  21. STERNBERG CN, Castellano D, de Bono J, Fizazi K, et al
    Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01862.
    PubMed     Abstract available


  22. ATTARD G, Brown LC, Clarke NW, Parmar MKB, et al
    Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01864.
    PubMed    


  23. SUPIOT S, Vaugier L, Pasquier D, Buthaud X, et al
    OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
    Eur Urol. 2021 Jul 8. pii: S0302-2838(21)01816.
    PubMed     Abstract available


  24. MARSDEN T, Ahmed HU, Emberton M
    An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, an
    Eur Urol. 2021 Jul 1. pii: S0302-2838(21)01817.
    PubMed     Abstract available


  25. BERGOUGNOUX A, Ea V, Paris F, Kalfa N, et al
    Reply to Zhongzhong Chen, Hua Xie, and Fang Chen's Letter to the Editor re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur U
    Eur Urol. 2021;80:e12-e13.
    PubMed    


  26. CHEN Z, Xie H, Chen F
    Re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur Urol 2021;79:507-515.
    Eur Urol. 2021;80:e10-e11.
    PubMed    


    June 2021
  27. SATAPATHY S, Das N, Sood A, Goyal S, et al
    Short-course (177)Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01818.
    PubMed    


  28. SHARMA V, Karnes RJ
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01806.
    PubMed    


  29. GLICKSMAN RM, Berlin A
    Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospect
    Eur Urol. 2021 Jun 19. pii: S0302-2838(21)01810.
    PubMed    


  30. CIMADAMORE A, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma o
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01807.
    PubMed    


  31. WILKINSON S, Ye H, Lis RT, Sowalsky AG, et al
    Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01808.
    PubMed    


  32. GHADJAR P, Hayoz S, Bernhard J, Zwahlen DR, et al
    Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
    Eur Urol. 2021 Jun 14. pii: S0302-2838(21)01802.
    PubMed     Abstract available


  33. TILKI D, Evans CP
    Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.
    Eur Urol. 2021 Jun 9. pii: S0302-2838(21)01805.
    PubMed    


  34. SUMANASURIYA S, Seed G, Parr H, Christova R, et al
    Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    Eur Urol. 2021 Jun 5. pii: S0302-2838(21)01799.
    PubMed     Abstract available


  35. CHOW AK, Vourganti S, Konety BR
    Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Eur Urol. 2021 Jun 3. pii: S0302-2838(21)01796.
    PubMed    


  36. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed    


  37. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed    


    May 2021
  38. SATISH P, Simpson B, Freeman A, Giganti F, et al
    Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk.
    Eur Urol. 2021 May 28. pii: S0302-2838(21)00355.
    PubMed    


  39. LIAUW SL
    High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00392.
    PubMed    


  40. PADHANI AR, Rouviere O, Schoots IG
    Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00393.
    PubMed    


  41. SWEENEY CJ, Martin AJ, Stockler MR, Begbie S, et al
    Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Eur Urol. 2021 May 21. pii: S0302-2838(21)00354.
    PubMed     Abstract available


  42. XU J, Isaacs WB
    Incorporation of Polygenic Risk Score into Guidelines for Inherited Risk Assessment for Prostate Cancer.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00323.
    PubMed    


  43. RAJWA P, Pradere B, Quhal F, Mori K, et al
    Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
    Eur Urol. 2021 May 18. pii: S0302-2838(21)00325.
    PubMed     Abstract available


  44. PHILIPSON RG, Romero T, Wong JK, Stish BJ, et al
    Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
    Eur Urol. 2021 May 10. pii: S0302-2838(21)00314.
    PubMed     Abstract available


  45. CHENG HH
    Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00308.
    PubMed    


  46. VAN POPPEL H, Hogenhout R, Albers P, van den Bergh RCN, et al
    Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European C
    Eur Urol. 2021 May 5. pii: S0302-2838(21)00297.
    PubMed    


  47. VAN DEN BROECK T, Oprea-Lager D, Moris L, Kailavasan M, et al
    A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2021 May 4. pii: S0302-2838(21)00298.
    PubMed     Abstract available


  48. EVANGELISTA L, Lopci E
    Re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Canc
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00296.
    PubMed    


  49. DARST BF, Sheng X, Eeles RA, Kote-Jarai Z, et al
    Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00253.
    PubMed     Abstract available


    April 2021
  50. KIM SE, Shin JI, Shoag JE
    Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Eur Urol. 2021 Apr 30. pii: S0302-2838(21)00251.
    PubMed    


  51. VALLE LF, Kishan AU
    Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MAST
    Eur Urol. 2021 Apr 29. pii: S0302-2838(21)00250.
    PubMed    


  52. BERCHUCK JE, Zhang Z, Silver R, Kwak L, et al
    Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2021 Apr 19. pii: S0302-2838(21)00237.
    PubMed     Abstract available


  53. ADELEKE S, Haroon A, Kasivisvanathan V
    Re: [(177)Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial.
    Eur Urol. 2021 Apr 16. pii: S0302-2838(21)00245.
    PubMed    


  54. CHU CE, Alshalalfa M, Sjostrom M, Zhao SG, et al
    Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00215.
    PubMed     Abstract available


  55. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00175.
    PubMed     Abstract available


  56. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed     Abstract available


  57. OKE O, Ranasinghe W, Tang C, Shaaban S, et al
    Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.
    Eur Urol. 2021 Apr 3. pii: S0302-2838(21)00228.
    PubMed    


    March 2021
  58. WILKINSON S, Ye H, Karzai F, Harmon SA, et al
    Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.
    Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00207.
    PubMed     Abstract available


  59. KUMARASWAMY A, Welker Leng KR, Westbrook TC, Yates JA, et al
    Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
    Eur Urol. 2021 Mar 27. pii: S0302-2838(21)00176.
    PubMed     Abstract available


  60. KWON DH, Booth CM, Prasad V
    Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Eur Urol. 2021 Mar 12. pii: S0302-2838(21)00168.
    PubMed     Abstract available


  61. VON EYBEN FE
    Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79:263-82.
    Eur Urol. 2021 Mar 9. pii: S0302-2838(21)00169.
    PubMed    


  62. GLICKSMAN RM, Metser U, Vines D, Valliant J, et al
    Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
    Eur Urol. 2021 Mar 5. pii: S0302-2838(21)00151.
    PubMed     Abstract available


  63. LESTINGI JFP, Trinh QD, Coelho RF, Pontes J Jr, et al
    Reply to Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montorsi's Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymp
    Eur Urol. 2021 Mar 5. pii: S0302-2838(21)00164.
    PubMed    


    February 2021
  64. BRIGANTI A, Gandaglia G, Graefen M, Joniau S, et al
    Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized P
    Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00144.
    PubMed    


  65. OH DY
    CD38 as a Novel Immunosuppressive Target in Prostate Cancer.
    Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00142.
    PubMed    


  66. AUGUGLIARO M, Pepa M, Marvaso G, Jereczek-Fossa BA, et al
    Re: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
    Eur Urol. 2021 Feb 22. pii: S0302-2838(21)00095.
    PubMed    


  67. FROEHNER M, Koch R, Graefen M
    Re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79:243-62: Comorbidity Measu
    Eur Urol. 2021 Feb 18. pii: S0302-2838(21)00089.
    PubMed    


  68. VAN DEN BERGH RCN, O'Hanlon S, Cornford P, Mottet N, et al
    Reply to Michael Froehner, Rainer Koch, and Markus Graefen's Letter to the Editor re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, an
    Eur Urol. 2021 Feb 16. pii: S0302-2838(21)00090.
    PubMed    


  69. GUPTA S, Heemers HV
    Treatment-induced Treatment Sensitization in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Feb 16. pii: S0302-2838(21)00088.
    PubMed    


  70. LESTINGI JFP, Guglielmetti GB, Trinh QD, Coelho RF, et al
    Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. Eur Urol. In press.
    Eur Urol. 2021 Feb 16. pii: S0302-2838(21)00082.
    PubMed    


  71. LAHOUD J, Doan P, Kim L, Patel MI, et al
    Perilesional Biopsies Increase Detection of Significant Prostate Cancer in Men with PI-RADS 4/5 Lesions: Validation of the PI-RADS Steering Committee Recommendation.
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00080.
    PubMed    


  72. HEIDENREICH A
    Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer.
    Eur Urol. 2021 Feb 13. pii: S0302-2838(21)00074.
    PubMed    


  73. LI H, Zhang Y, Li D, Ma X, et al
    Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
    Eur Urol. 2021 Feb 9. pii: S0302-2838(21)00078.
    PubMed     Abstract available


  74. SCIALPI M, Scialpi P, D'Andrea A, Di Blasi A, et al
    Re: Ivo G. Schoots, Jelle O. Barentsz, Leonardo K. Bittencourt, et al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-naive Men with Suspected Prostate Cancer: Narrative Review. Am J Roentgenol 2021;216:3-19: PI-RADS v2.1 and Futu
    Eur Urol. 2021 Feb 8. pii: S0302-2838(21)00061.
    PubMed    


  75. STOPSACK KH
    Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health?
    Eur Urol. 2021 Feb 4. pii: S0302-2838(21)00010.
    PubMed    


  76. CONNOR MJ, Khoo V, Watson V, Ahmed HU, et al
    Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer.
    Eur Urol. 2021 Feb 3. pii: S0302-2838(21)00068.
    PubMed    


  77. KOEHNE EL, Flanigan RC
    Re: Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Eur Urol. 2021 Feb 3. pii: S0302-2838(21)00065.
    PubMed    


  78. JIANG DM, Fallah-Rad N, Lee R, Ng P, et al
    Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021;79:177-179.
    PubMed     Abstract available


  79. RANASINGHE W, Shapiro DD, Hwang H, Wang X, et al
    Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
    Eur Urol. 2021;79:298-306.
    PubMed     Abstract available


  80. HU JC, Basourakos SP, Futterer J
    Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Eur Urol. 2021;79:167-169.
    PubMed     Abstract available


    January 2021
  81. MERSEBURGER AS, Waldron N, Ribal MJ, Heidenreich A, et al
    Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Eur Urol. 2021 Jan 22. pii: S0302-2838(20)31025.
    PubMed     Abstract available


  82. FU BC, Tabung FK, Pernar CH, Wang W, et al
    Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer.
    Eur Urol. 2021 Jan 6. pii: S0302-2838(20)31016.
    PubMed     Abstract available


  83. CASANOVA-SALAS I, Athie A, Boutros PC, Del Re M, et al
    Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
    Eur Urol. 2021 Jan 6. pii: S0302-2838(20)31023.
    PubMed     Abstract available


  84. DEEK MP, Van der Eecken K, Phillips R, Parikh NR, et al
    The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31026.
    PubMed     Abstract available


  85. SWAMI U, Antonarakis ES, Agarwal N
    Reply to Salma Kaochar, Nicholas Mitsiades' Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur U
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)30957.
    PubMed    


  86. ALLEN-TEJERINA AM, Rallis KS, Szabados B
    Re: Roman Sosnowski, Hubert Kamecki, Steven Joniau, Jochen Walz, Zachary Klaassen, Joan Palou. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. Eur Urol. In press. https://doi.org/10.1016/j
    Eur Urol. 2021;79:e26-e27.
    PubMed    


  87. VAN DIJK N, Gomez de Liano Lista A, Szabados B, Powles T, et al
    Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gomez de Liano Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-P
    Eur Urol. 2021;79:e20-e21.
    PubMed    


  88. KYPRIANOU N
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-cell Analysis.
    Eur Urol. 2021;79:161-162.
    PubMed    


  89. MORGANS AK
    Minimizing Risk to Maximize Outcomes.
    Eur Urol. 2021;79:54-55.
    PubMed    


  90. CHEN Y, Wang Z, Liu J
    Re: Giovanni Lavorgna, Riccardo Vago, Francesco Montorsi, Andrea Salonia. Surnames in Y-Chromosome-related Diseases: A New Tool for the Urologist? Eur Urol 2020;77:767-8.
    Eur Urol. 2021;79:e37.
    PubMed    


  91. DELL'OGLIO P, Meershoek P, Maurer T, Wit EMK, et al
    A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy.
    Eur Urol. 2021;79:124-132.
    PubMed     Abstract available


  92. STAVRINIDES V, Syer T, Hu Y, Giganti F, et al
    False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naive Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Eur Urol. 2021;79:20-29.
    PubMed     Abstract available


    December 2020
  93. VAN POPPEL H, Hogenhout R, Albers P, van den Bergh RCN, et al
    Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission.
    Eur Urol. 2020 Dec 28. pii: S0302-2838(20)30958.
    PubMed     Abstract available


  94. KAOCHAR S, Mitsiades N
    Re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652-6: Can Mutant SPOP Become an Actionable Biomarker
    Eur Urol. 2020 Dec 24. pii: S0302-2838(20)30960.
    PubMed    


  95. DE BONO J, Hussain M, Kang J
    Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olapar
    Eur Urol. 2020 Dec 22. pii: S0302-2838(20)30964.
    PubMed    


  96. STOPSACK KH
    Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructi
    Eur Urol. 2020 Dec 22. pii: S0302-2838(20)30966.
    PubMed    


  97. FRASER M
    Evidence for Focal Grade Group Progression in Low-risk Prostate Cancer.
    Eur Urol. 2020 Dec 20. pii: S0302-2838(20)30886.
    PubMed    


  98. MORI K, Egawa S, Shariat SF
    Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2020 Dec 20. pii: S0302-2838(20)30935.
    PubMed    


  99. DE FERIA CARDET RE, Hofman MS, Segard T, Yim J, et al
    Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    Eur Urol. 2020 Dec 16. pii: S0302-2838(20)30946.
    PubMed     Abstract available


  100. ORCZYK C, Marsden T, Emberton M
    Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.
    Eur Urol. 2020 Dec 16. pii: S0302-2838(20)30949.
    PubMed    


  101. PATEL V
    Reply to Francesco Montorsi, Giorgio Gandaglia, Christoph Wurnschimmel, Markus Graefen, Alberto Briganti, and Hartwig Huland's Letter to the Editor re: Paolo Afonso de Carvalho, Joao A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release
    Eur Urol. 2020 Dec 14. pii: S0302-2838(20)30849.
    PubMed    


  102. VALLE LF, Lehrer EJ, Markovic D, Elashoff D, et al
    A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
    Eur Urol. 2020 Dec 10. pii: S0302-2838(20)30874.
    PubMed     Abstract available


  103. MACEK P, Sanchez-Salas R, Cathelineau X
    Re: High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer. Initial Outcomes of a United States Series.
    Eur Urol. 2020 Dec 8. pii: S0302-2838(20)30940.
    PubMed    


  104. YAMOAH K, Awasthi S, Mahal BA, Zhao SG, et al
    Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.
    Eur Urol. 2020 Dec 7. pii: S0302-2838(20)30939.
    PubMed     Abstract available


  105. FEUERECKER B, Tauber R, Knorr K, Heck M, et al
    Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30877.
    PubMed     Abstract available


  106. JAIRATH NK, Dal Pra A, Vince R Jr, Dess RT, et al
    A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30885.
    PubMed     Abstract available


  107. LESTINGI JFP, Guglielmetti GB, Trinh QD, Coelho RF, et al
    Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
    Eur Urol. 2020 Dec 5. pii: S0302-2838(20)30941.
    PubMed     Abstract available


  108. RODRIGUEZ-SANCHEZ L, Crehange G, Bennamoun M, Macek P, et al
    Re: Adjuvant Radiotherapy Versus Early Salvage Radiotherapy plus Short-term Androgen Deprivation Therapy in Men with Localised Prostate Cancer After Radical Prostatectomy (GETUG-AFU 17): A Randomised, Phase 3 Trial.
    Eur Urol. 2020 Dec 2. pii: S0302-2838(20)30933.
    PubMed    


  109. NOVARA G, Checcucci E, Crestani A, Abrate A, et al
    Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?
    Eur Urol. 2020;78:786-811.
    PubMed     Abstract available


  110. KWON DH, Friedlander TW
    Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials.
    Eur Urol. 2020;78:854-855.
    PubMed    


  111. KASTELAN Z, Hudolin T, Kulis T, Penezic L, et al
    Extraperitoneal Radical Prostatectomy with the Senhance Robotic Platform: First 40 Cases.
    Eur Urol. 2020;78:932-934.
    PubMed    


    November 2020
  112. QUIGLEY DA
    One of These Things is Not Like the Others: Targeting ATM-mutant Prostate Cancer.
    Eur Urol. 2020 Nov 27. pii: S0302-2838(20)30882.
    PubMed    


  113. SHI Z, Platz EA, Wei J, Na R, et al
    Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
    Eur Urol. 2020 Nov 27. pii: S0302-2838(20)30878.
    PubMed     Abstract available


  114. MA SJ, Oladeru OT, Wang K, Attwood K, et al
    Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals.
    Eur Urol. 2020 Nov 26. pii: S0302-2838(20)30873.
    PubMed     Abstract available


  115. HUEBNER NA, Shariat SF
    Clinical Impact and Statistical Significance of Multiparametric Magnetic Resonance Imaging for Local Staging of Prostate Cancer.
    Eur Urol. 2020 Nov 24. pii: S0302-2838(20)30860.
    PubMed    


  116. DE WIT R, Tombal B, Freedland S
    Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30805.
    PubMed     Abstract available


  117. DA SILVA FC, Algaba F
    Re: Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30852.
    PubMed    


  118. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    PubMed    


  119. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    PubMed    


  120. EPSTEIN JI, Kryvenko ON
    A Comparison of Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines.
    Eur Urol. 2020 Nov 11. pii: S0302-2838(20)30853.
    PubMed     Abstract available


  121. NEEB A, Herranz N, Arce-Gallego S, Miranda S, et al
    Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
    Eur Urol. 2020 Nov 8. pii: S0302-2838(20)30836.
    PubMed     Abstract available


  122. MOTTET N, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2020 Nov 7. pii: S0302-2838(20)30769.
    PubMed     Abstract available


  123. FERREIRA COELHO R, Afonso de Carvalho P, Betoni Guglielmetti G, Dener Cordeiro M, et al
    Reply to Francesco Montorsi, Giorgio Gandaglia, Christoph Wurnschimmel, Markus Graefen, Alberto Briganti, and Hartwig Huland's Letter to the Editor re: Paolo Afonso de Carvalho, Joao A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release
    Eur Urol. 2020 Nov 5. pii: S0302-2838(20)30689.
    PubMed    


  124. BANGMA CH, van Leenders GJLH, Roobol MJ, Schoots IG, et al
    Restricting False-positive Magnetic Resonance Imaging Scans to Reduce Overdiagnosis of Prostate Cancer.
    Eur Urol. 2020 Nov 5. pii: S0302-2838(20)30790.
    PubMed    


  125. VICKERS A, Carlsson SV, Cooperberg M
    Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duan's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified b
    Eur Urol. 2020 Nov 3. pii: S0302-2838(20)30786.
    PubMed    


  126. RUIZ DE PORRAS V, Wang XC, Palomero L, Marin-Aguilera M, et al
    Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
    Eur Urol. 2020 Nov 2. pii: S0302-2838(20)30778.
    PubMed     Abstract available


  127. GOMEZ SL, Washington SL 3rd, Cheng I, Huang FW, et al
    Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends.
    Eur Urol. 2020 Nov 2. pii: S0302-2838(20)30811.
    PubMed    


  128. COOPERBERG MR, Cowan JE, Lindquist KJ, Kobayashi Y, et al
    Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
    Eur Urol. 2020 Nov 1. pii: S0302-2838(20)30694.
    PubMed     Abstract available


  129. GHOREIFI A, Djaladat H
    Re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
    Eur Urol. 2020;78:e184-e185.
    PubMed    


  130. LIEDBERG F, Kollberg P, Allerbo M, Baseckas G, et al
    Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In pres
    Eur Urol. 2020;78:e186-e187.
    PubMed    


  131. GIANNARINI G, Ficarra V, Valotto C
    Re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur U
    Eur Urol. 2020;78:e188-e189.
    PubMed    


  132. EASTHAM JA
    Salvage Pelvic Lymph Node Dissection for Nodal Recurrence After Radical Prostatectomy Results in Minimal Clinical Benefit.
    Eur Urol. 2020;78:670.
    PubMed    


    October 2020
  133. BREMBILLA G, Takwoingi Y, Kasivisvanathan V
    Tackling Interobserver Variability in Multiparametric Magnetic Resonance Imaging (MRI): Is MRI Even Better than We Think for Prostate Cancer Diagnosis?
    Eur Urol. 2020 Oct 31. pii: S0302-2838(20)30812.
    PubMed     Abstract available


  134. SUN Y, Sun F, Wei Q, Huang J, et al
    Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6.
    Eur Urol. 2020 Oct 26. pii: S0302-2838(20)30779.
    PubMed    


  135. MCHENRY MB, Drake CG, Fizazi K
    Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metas
    Eur Urol. 2020 Oct 26. pii: S0302-2838(20)30789.
    PubMed    


  136. LUDMIR EB, McCaw ZR, Wei LJ
    Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Surviv
    Eur Urol. 2020 Oct 24. pii: S0302-2838(20)30776.
    PubMed    


  137. COOK MB, Hurwitz LM, Geczik AM, Butler EN, et al
    An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.
    Eur Urol. 2020 Oct 19. pii: S0302-2838(20)30768.
    PubMed     Abstract available


  138. CORNFORD P, van den Bergh RCN, Briers E, den Broeck TV, et al
    EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2020 Oct 7. pii: S0302-2838(20)30773.
    PubMed     Abstract available


  139. MONTORSI F, Gandaglia G, Wurnschimmel C, Graefen M, et al
    Re: Paolo Afonso de Carvalho, Joao A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes.
    Eur Urol. 2020 Oct 6. pii: S0302-2838(20)30690.
    PubMed    


  140. BRAVI CA, Montorsi F, Briganti A
    Reply to Verane Achard, Alan Dal Pra, and Thomas Zilli's Letter to the Editor re: Carlo A. Bravi, Nicola Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prost
    Eur Urol. 2020 Oct 3. pii: S0302-2838(20)30759.
    PubMed    


  141. DIAMAND R, Ploussard G, Roumiguie M, Oderda M, et al
    External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Eur Urol. 2020 Oct 3. pii: S0302-2838(20)30764.
    PubMed     Abstract available


  142. STOPSACK KH
    Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
    Eur Urol. 2020 Oct 1. pii: S0302-2838(20)30716.
    PubMed     Abstract available


  143. THOMPSON J, Amin A, Stricker P
    Magnetic Resonance Imaging Improves Selection for Active Surveillance and Can Extend the Interval Between Biopsies.
    Eur Urol. 2020;78:518-519.
    PubMed    


  144. KARABAY E, Tinay I
    Re: Marc-Oliver Grimm, Antione G. van der Heijden, Marc Colombel, et al. Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Assoc
    Eur Urol. 2020;78:e161-e162.
    PubMed    


    September 2020
  145. SAAD F, Sternberg CN, Efstathiou E, Fizazi K, et al
    Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Eur Urol. 2020 Sep 30. pii: S0302-2838(20)30642.
    PubMed     Abstract available


  146. ACHARD V, Dal Pra A, Zilli T
    Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol. In press. https://doi.o
    Eur Urol. 2020 Sep 29. pii: S0302-2838(20)30695.
    PubMed    


  147. DARST BF
    Findings from a Genetic Sequencing Investigation of Men with Familial and Aggressive Prostate Cancer.
    Eur Urol. 2020 Sep 26. pii: S0302-2838(20)30693.
    PubMed    


  148. ROYCE TJ, Wang AZ, Chen RC
    Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer.
    Eur Urol. 2020 Sep 24. pii: S0302-2838(20)30721.
    PubMed    


  149. CUMBERBATCH M, Condon B, Lawrentschuk N, Murphy DG, et al
    Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 Sep 23. pii: S0302-2838(20)30724.
    PubMed    


  150. BOEVE L, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
    Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORR
    Eur Urol. 2020 Sep 22. pii: S0302-2838(20)30640.
    PubMed     Abstract available


  151. BAGGULEY D, Ong S, Lawrentschuk N, Murphy DG, et al
    Re: Enzalutamide and Survival in Non-metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 Sep 16. pii: S0302-2838(20)30701.
    PubMed    


  152. GUL M, Serefoglu EC
    Is Infertility a Predictor of Prostate Cancer?
    Eur Urol. 2020 Sep 16. pii: S0302-2838(20)30696.
    PubMed    


  153. MAZZONE E, Dell'Oglio P, Rosiello G, Puliatti S, et al
    Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2020 Sep 14. pii: S0302-2838(20)30700.
    PubMed     Abstract available


  154. PACHYNSKI RK
    A "Tail" of Immunotherapy in Metastatic Prostate Cancer.
    Eur Urol. 2020 Sep 12. pii: S0302-2838(20)30691.
    PubMed    


  155. SMITH MR, Saad F, Chowdhury S, Oudard S, et al
    Apalutamide and Overall Survival in Prostate Cancer.
    Eur Urol. 2020 Sep 6. pii: S0302-2838(20)30628.
    PubMed     Abstract available


  156. MIYAMOTO DT, Lee RJ
    PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer.
    Eur Urol. 2020 Sep 5. pii: S0302-2838(20)30684.
    PubMed    


  157. KELLOKUMPU-LEHTINEN PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, Astrom L, et al
    Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].
    Eur Urol. 2020 Sep 3. pii: S0302-2838(20)30685.
    PubMed    


  158. CUMBERBATCH MG, Murphy DG
    Focal Therapy: When Nothing Is Sure, Everything Is Possible.
    Eur Urol. 2020;78:379-380.
    PubMed    


  159. LAVIANA AA, Luckenbaugh AN, Wallis CJD
    Seeking the Truth: Understanding the Impact of Missing Data on the Validity of the New Surveillance, Epidemiology and End Results Prostate with Watchful Waiting Database.
    Eur Urol. 2020;78:345-346.
    PubMed    


    August 2020
  160. MAHAL BA, D'Amico AV, Nguyen PL
    Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Eur Urol. 2020 Aug 28. pii: S0302-2838(20)30602.
    PubMed    


  161. DE SANTIS M, Mottet N, Cornford P, Gillessen S, et al
    Precision Oncology for Metastatic Prostate Cancer: Translation into Practice.
    Eur Urol. 2020 Aug 27. pii: S0302-2838(20)30638.
    PubMed     Abstract available


  162. PADHANI AR, Barentsz J, Weinreb J, Schoots I, et al
    Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.
    Eur Urol. 2020 Aug 25. pii: S0302-2838(20)30444.
    PubMed    


  163. VAN LEENDERS GJLH, van der Kwast TH, Iczkowski KA
    The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading.
    Eur Urol. 2020 Aug 23. pii: S0302-2838(20)30618.
    PubMed     Abstract available


  164. RADTKE JP, Nyarangi-Dix J, Wiesenfarth M, Hadaschik B, et al
    Re: The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Pr
    Eur Urol. 2020 Aug 23. pii: S0302-2838(20)30636.
    PubMed    


  165. ANING J, McCoubrie P, Oxley J
    Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Patholo
    Eur Urol. 2020 Aug 21. pii: S0302-2838(20)30607.
    PubMed    


  166. MORIS L, Mottet N, Wiegel T
    Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostat
    Eur Urol. 2020 Aug 21. pii: S0302-2838(20)30621.
    PubMed    


  167. SHORE ND, Dearnaley D, Tombal B
    Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-9
    Eur Urol. 2020 Aug 21. pii: S0302-2838(20)30606.
    PubMed    


  168. FIZAZI K, Drake CG, Beer TM, Kwon ED, et al
    Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
    Eur Urol. 2020 Aug 15. pii: S0302-2838(20)30604.
    PubMed     Abstract available


  169. MONTORSI F, Salonia A, Briganti A
    Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30603.
    PubMed    


  170. SCHAID DJ, McDonnell SK, FitzGerald LM, DeRycke L, et al
    Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30614.
    PubMed     Abstract available


  171. GANDAGLIA G, Montorsi F, Briganti A
    Reply to Jonathan Aning, Paul McCoubrie, and Jon Oxley's Letter to the Editor re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targ
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30619.
    PubMed    


  172. DI LORENZO G, Autorino R
    Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn't Gold.
    Eur Urol. 2020 Aug 13. pii: S0302-2838(20)30612.
    PubMed     Abstract available


  173. MONTORSI F, Gandaglia G, Fossati N, Salonia A, et al
    Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.035.
    Eur Urol. 2020 Aug 11. pii: S0302-2838(20)30540.
    PubMed    


  174. SOLOWAY MS, Lokeshwar SD
    The Fallacy of "Definitive Therapy" for Prostate Cancer.
    Eur Urol. 2020 Aug 6. pii: S0302-2838(20)30545.
    PubMed     Abstract available


  175. MODI PK, Eggener SE
    Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints.
    Eur Urol. 2020;78:161-162.
    PubMed    


  176. BABJUK M
    Reply to Can Lu and Xiao Guan's Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022
    Eur Urol. 2020;78:e73-e74.
    PubMed    


  177. LU C, Guan X
    Re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022.
    Eur Urol. 2020;78:e71-e72.
    PubMed    


    July 2020
  178. STAVRINIDES V, Giganti F, Emberton M, Moore CM, et al
    Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active S
    Eur Urol. 2020 Jul 22. pii: S0302-2838(20)30542.
    PubMed    


  179. MORIS L, Van den Broeck T, Wiegel T
    Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: A
    Eur Urol. 2020 Jul 16. pii: S0302-2838(20)30536.
    PubMed    


  180. FUNADA S, Yoshioka T, Luo Y
    Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Eur Urol. 2020 Jul 15. pii: S0302-2838(20)30517.
    PubMed    


  181. VAN DEN BERGH RCN, Rouviere O, van der Kwast T
    Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.
    Eur Urol. 2020 Jul 10. pii: S0302-2838(20)30432.
    PubMed    


  182. STAVRINIDES V, Giganti F, Emberton M, Moore CM, et al
    Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A L
    Eur Urol. 2020 Jul 8. pii: S0302-2838(20)30467.
    PubMed    


  183. LOPCI E, Lazzeri M
    Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centr
    Eur Urol. 2020 Jul 8. pii: S0302-2838(20)30514.
    PubMed    


  184. BRYCE AH, Sartor O, de Bono J
    DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
    Eur Urol. 2020 Jul 4. pii: S0302-2838(20)30449.
    PubMed     Abstract available


  185. SALAMI SS, Tosoian JJ, Nallandhighal S, Jones TA Jr, et al
    Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30470.
    PubMed     Abstract available


  186. KREUZ M, Otto DJ, Fuessel S, Blumert C, et al
    ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer.
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30428.
    PubMed     Abstract available


  187. CHU CE, Lonergan PE, Washington SL, Cowan JE, et al
    Mutiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30459.
    PubMed     Abstract available


  188. VICKERS A, Carlsson SV, Cooperberg M
    Reply to Roderick C.N. van den Bergh, Olivier Rouviere, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is
    Eur Urol. 2020 Jul 3. pii: S0302-2838(20)30525.
    PubMed    


  189. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
    Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30472.
    PubMed     Abstract available


  190. DI LORENZO G, Autorino R
    Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30440.
    PubMed    


  191. NEAL DE, Metcalfe C, Donovan JL, Lane JA, et al
    Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30392.
    PubMed    


  192. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
    Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30507.
    PubMed     Abstract available


  193. MARKOWSKI MC, Wang H, Sullivan R, Rifkind I, et al
    A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30471.
    PubMed     Abstract available


  194. FANKHAUSER CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, et al
    Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30413.
    PubMed    


  195. MASSARI F, Mollica V
    Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30442.
    PubMed    


  196. PLOUSSARD G
    Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30446.
    PubMed    


  197. SWAMI U, Isaacsson Velho P, Nussenzveig R, Chipman J, et al
    Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30462.
    PubMed     Abstract available


  198. R ZLOTTA A, V Carlsson S, Finelli A, E Fleshner N, et al
    Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: Against increasing PSA threshold to 10 ng/ml.
    Eur Urol. 2020 Jul 2. pii: S0302-2838(20)30455.
    PubMed    


  199. CAZZANIGA W
    Re: Changes in Treatment and Mortality in Men with Locally Advanced Prostate Cancer Between 2000 and 2016: A Nationwide, Population-based Study in Sweden.
    Eur Urol. 2020 Jul 1. pii: S0302-2838(20)30447.
    PubMed    


  200. CHU CE, Lonergan PE, Carroll PR
    Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.035.
    Eur Urol. 2020 Jul 1. pii: S0302-2838(20)30466.
    PubMed    


  201. BORGHESI M, Suardi N, Terrone C
    Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: The future of PSA screening by reconsidering prostate cancer mortality.
    Eur Urol. 2020 Jul 1. pii: S0302-2838(20)30457.
    PubMed    


  202. WATERHOUSE JV, Hull JH, Linch M
    Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?
    Eur Urol. 2020;78:9-10.
    PubMed     Abstract available


    June 2020
  203. ABUFARAJ M, Iwata T, Kimura S, Haddad A, et al
    Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30429.
    PubMed     Abstract available


  204. CHIN JL, Bauman GS
    Re: Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30445.
    PubMed    


  205. TROYER D
    High-risk Prostate Cancer Patients Are Not All Alike.
    Eur Urol. 2020 Jun 27. pii: S0302-2838(20)30453.
    PubMed    


  206. BROOKMAN-MAY SD, May M
    Re: Androgen-deprivation Therapies for Prostate Cancer and Risk of Infection by SARS-CoV-2: A Population-based Study (n=4532).
    Eur Urol. 2020 Jun 16. pii: S0302-2838(20)30443.
    PubMed    


  207. MUKHERJI D, Omlin A, Pezaro C
    Living Longer and Better with Advanced Prostate Cancer.
    Eur Urol. 2020 Jun 15. pii: S0302-2838(20)30360.
    PubMed    


  208. PADHANI AR, Villeirs G, Ahmed HU, Panebianco V, et al
    Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound.
    Eur Urol. 2020 Jun 12. pii: S0302-2838(20)30416.
    PubMed    


  209. MORIS L, Mottet N, Wiegel T
    Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostat
    Eur Urol. 2020 Jun 11. pii: S0302-2838(20)30414.
    PubMed    


  210. GREGUCCI F, Carbonara R, Fiorentino A
    Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Eur Urol. 2020 Jun 10. pii: S0302-2838(20)30412.
    PubMed    


  211. NYBERG T, Frost D, Barrowdale D, Evans DG, et al
    Prostate Cancer Risk by BRCA2 Genomic Regions.
    Eur Urol. 2020 Jun 10. pii: S0302-2838(20)30345.
    PubMed     Abstract available


  212. ARMSTRONG AJ, Lin P, Tombal B, Saad F, et al
    Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
    Eur Urol. 2020 Jun 9. pii: S0302-2838(20)30329.
    PubMed     Abstract available


  213. LEBASTCHI AH, George AK, Polascik TJ, Coleman J, et al
    Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
    Eur Urol. 2020 Jun 9. pii: S0302-2838(20)30358.
    PubMed     Abstract available


  214. LAVORGNA G, Montorsi F, Salonia A
    Re: Hung-Ming Lam, Holly M. Nguyen, Mark P. Labrecque, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcrip
    Eur Urol. 2020 Jun 8. pii: S0302-2838(20)30363.
    PubMed    


  215. SIMPSON BS, Carmona Echeverria LM, Norris JM, Ahmed HU, et al
    Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.
    Eur Urol. 2020 Jun 8. pii: S0302-2838(20)30342.
    PubMed    


  216. CHESNUT GT, Vickers AJ, Ehdaie B
    Reply to Benjamin S. Simpson, Lina M. Carmona Echeverria, Joseph M. Norris, Hashim U. Ahmed, Caroline M. Moore, and Hayley C. Whitaker's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnet
    Eur Urol. 2020 Jun 7. pii: S0302-2838(20)30355.
    PubMed    


  217. YAO J, Pleass HCC, Lau HMH
    Re: Andrea Gallioli, Angelo Territo, Romain Boissier, et al. Learning Curve in Robotic-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.00
    Eur Urol. 2020;77:e165.
    PubMed    


    May 2020
  218. FETTKE H, Kwan EM, Docanto MM, Bukczynska P, et al
    Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
    Eur Urol. 2020 May 30. pii: S0302-2838(20)30219.
    PubMed     Abstract available


  219. KISHAN AU, Romero T, Alshalalfa M, Liu Y, et al
    Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
    Eur Urol. 2020 May 24. pii: S0302-2838(20)30349.
    PubMed     Abstract available


  220. MONDA SM, Dall'Era MA
    What Are We Missing? Magnetic Resonance Imaging-negative Clinically Significant Prostate Cancer in PROMIS.
    Eur Urol. 2020 May 22. pii: S0302-2838(20)30351.
    PubMed    


  221. HERBERTS C, Murtha AJ, Fu S, Wang G, et al
    Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2020 May 22. pii: S0302-2838(20)30326.
    PubMed     Abstract available


  222. SATHIANATHEN NJ, Omer A, Harriss E, Davies L, et al
    Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
    Eur Urol. 2020 May 20. pii: S0302-2838(20)30223.
    PubMed     Abstract available


  223. MAI Z, Yuan R
    Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30337.
    PubMed    


  224. STABILE A, Orczyk C, Giganti F, Moschini M, et al
    The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.
    Eur Urol. 2020 May 19. pii: S0302-2838(20)30336.
    PubMed     Abstract available


  225. DARST BF, Wan P, Sheng X, Bensen JT, et al
    A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.
    Eur Urol. 2020 May 11. pii: S0302-2838(20)30328.
    PubMed     Abstract available


  226. LA TAILLE A, Ingels A
    Re: Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Eur Urol. 2020 May 10. pii: S0302-2838(20)30244.
    PubMed    


  227. VICKERS A, Carlsson SV, Cooperberg M
    Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30248.
    PubMed     Abstract available


  228. WALZ J
    Re: Prostate-specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30237.
    PubMed    


  229. ZLOTTA AR, Sadeghian A
    Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-based, Diagnostic Study.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30242.
    PubMed    


  230. VILLERS A, Olivier J
    Re: Long-term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    Eur Urol. 2020 May 7. pii: S0302-2838(20)30235.
    PubMed    


  231. RODRIGUEZ SANCHEZ L, Macek P, Barbe Y, Cathelineau X, et al
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Eur Urol. 2020 May 6. pii: S0302-2838(20)30254.
    PubMed    


  232. CHESNUT GT, Vertosick EA, Ehdaie B
    Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men
    Eur Urol. 2020 May 5. pii: S0302-2838(20)30318.
    PubMed    


  233. ZELIC R, Garmo H, Zugna D, Stattin P, et al
    Corrigendum re "Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study" [Eur Urol 2020;77:180-8].
    Eur Urol. 2020 May 5. pii: S0302-2838(20)30191.
    PubMed    


  234. MARCISCANO AE, Barbieri CE
    CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30239.
    PubMed    


  235. RADTKE JP, Hadaschik B
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30246.
    PubMed    


  236. FROEHNER M, Koch R, Thomas C
    Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Eur Urol. 2020 May 4. pii: S0302-2838(20)30151.
    PubMed    


  237. KANAYAMA M, Luo J
    Predictive Biomarkers in Prostate Cancer: Is It Time To Go "All In" on Liquid Biopsies?
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30321.
    PubMed    


  238. ALBERTSEN PC
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2020 May 3. pii: S0302-2838(20)30249.
    PubMed    


  239. NORRIS JM, Carmona Echeverria LM, Bott SRJ, Brown LC, et al
    What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.
    Eur Urol. 2020 May 1. pii: S0302-2838(20)30261.
    PubMed     Abstract available


  240. HADASCHIK B, Herrmann K
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study.
    Eur Urol. 2020 May 1. pii: S0302-2838(20)30319.
    PubMed    


    April 2020
  241. DU J, Liu Y, Yan W
    Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://d
    Eur Urol. 2020 Apr 30. pii: S0302-2838(20)30245.
    PubMed    


  242. STAVRINIDES V, Giganti F, Trock B, Punwani S, et al
    Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Eur Urol. 2020 Apr 29. pii: S0302-2838(20)30210.
    PubMed     Abstract available


  243. SACHDEV S, Zhang H, Hussain M
    Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer.
    Eur Urol. 2020 Apr 25. pii: S0302-2838(20)30228.
    PubMed    


  244. STENZL A, Dunshee C, De Giorgi U, Alekseev B, et al
    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
    Eur Urol. 2020 Apr 23. pii: S0302-2838(20)30194.
    PubMed     Abstract available


  245. MOSCHOVAS MC, Sighinolfi MC, Rocco B, Bhat S, et al
    Balancing the Effects of COVID-19 Against Potential Progression and Mortality in High-risk Prostate Cancer.
    Eur Urol. 2020 Apr 21. pii: S0302-2838(20)30260.
    PubMed    


  246. MATTEI A, Wurnschimmel C, Baumeister P, Hyseni A, et al
    Standardized and Simplified Robot-assisted Superextended Pelvic Lymph Node Dissection for Prostate Cancer: The Monoblock Technique.
    Eur Urol. 2020 Apr 20. pii: S0302-2838(20)30207.
    PubMed     Abstract available


  247. WILT TJ, Dahm P, Brawer MK
    Reply to Roderick C.N. van den Bergh, Massimo Valerio, Derya Tilki, and Giorgio Gandaglia's Letter to the Editor re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Ext
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30222.
    PubMed    


  248. VAN DEN BERGH RCN, Valerio M, Tilki D, Gandaglia G, et al
    Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https:/
    Eur Urol. 2020 Apr 14. pii: S0302-2838(20)30221.
    PubMed    


  249. HESS BA JR
    Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Ozguroglu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone
    Eur Urol. 2020 Apr 11. pii: S0302-2838(20)30193.
    PubMed    


  250. COOPERBERG MR, Lin DW
    Active Surveillance for Prostate Cancer: A 2020 Vision.
    Eur Urol. 2020 Apr 10. pii: S0302-2838(20)30152.
    PubMed    


  251. DEARNALEY DP, Saltzstein DR, Sylvester JE, Karsh L, et al
    The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-g
    Eur Urol. 2020 Apr 6. pii: S0302-2838(20)30142.
    PubMed     Abstract available


  252. CARLSSON SV, Eastham JA, Crawford ED, Harris RG, et al
    "PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older.
    Eur Urol. 2020 Apr 6. pii: S0302-2838(20)30203.
    PubMed     Abstract available


  253. GANDAGLIA G, Martini A, Ploussard G, Fossati N, et al
    External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
    Eur Urol. 2020 Apr 5. pii: S0302-2838(20)30198.
    PubMed     Abstract available


  254. WANG Y, Xiong Y, Wang X
    Re: Zhengzheng Xu, Guangzhe Ge, Bao Guan, et al. Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profiles. Eur Urol 2020;77:288-90.
    Eur Urol. 2020;77:e90.
    PubMed    


  255. ZHENGZHENG X, Ge G, Guan B, Lei Z, et al
    Reply to Yejinpeng Wang, Yaoyi Xiong, and Xinghuan Wang's Letter to the Editor re: Zhengzheng Xu, Guangzhe Ge, Bao Guan, et al. Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profi
    Eur Urol. 2020;77:e91-e92.
    PubMed    


  256. CIMADAMORE A, Scarpelli M, Cheng L, Lopez-Beltran A, et al
    Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didact
    Eur Urol. 2020;77:e100-e102.
    PubMed    


    March 2020
  257. VON EYBEN FE, Bauman G, Soydal C, Paganelli G, et al
    Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012
    Eur Urol. 2020 Mar 25. pii: S0302-2838(20)30153.
    PubMed    


  258. SHARMA V, Jeffrey Karnes R
    "To Serve and ProtecT": Has the Pendulum Swung Too Far Towards Surveillance?
    Eur Urol. 2020;77:331-332.
    PubMed    


    February 2020
  259. EPSTEIN JI
    Is There Enough Support for a New Prostate Grading System Factoring in Intraductal Carcinoma and Cribriform Cancer?
    Eur Urol. 2020;77:199-200.
    PubMed    


  260. ROSARIO DJ, Bourke L
    Cardiovascular Disease and the Androgen Receptor: Here We Go Again?
    Eur Urol. 2020;77:167-169.
    PubMed    


    January 2020
  261. MISRAI V, Rijo E, Zorn KC, Barry-Delongchamps N, et al
    Reply to Francesco Montorsi, Paolo Capogrosso, Andrea Salonia's Letter to the Editor re: Vincent Misrai, Enrique Rijo, Kevin C. Zorn, Nicolas Barry-Delongchamps, Aurelien Descazeaud. Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction
    Eur Urol. 2020;77:e19-e20.
    PubMed    


  262. CHEN RC
    Randomized Trials and the Goldilocks Problem.
    Eur Urol. 2020;77:11-13.
    PubMed    


    September 2019
  263. SHI MJ, Meng XY, Chen CL, Dyrskjot L, et al
    Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Can
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30656.
    PubMed    


    August 2019
  264. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    PubMed    


    May 2019
  265. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    PubMed    


  266. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: